CNS Pharmaceuticals (NASDAQ:CNSP) Releases Earnings Results, Misses Expectations By $4.78 EPS

CNS Pharmaceuticals (NASDAQ:CNSP) posted its earnings results on Monday. The company reported ($10.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.37) by ($4.78), FiscalAI reports.

CNS Pharmaceuticals Price Performance

CNSP opened at $2.39 on Wednesday. The business has a fifty day simple moving average of $3.66 and a 200 day simple moving average of $6.10. The company has a market capitalization of $1.48 million, a PE ratio of -0.08 and a beta of 2.70. CNS Pharmaceuticals has a 1 year low of $2.06 and a 1 year high of $34.80.

Institutional Investors Weigh In On CNS Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Boothbay Fund Management LLC bought a new stake in shares of CNS Pharmaceuticals in the fourth quarter valued at about $71,000. Ikarian Capital LLC bought a new position in CNS Pharmaceuticals during the fourth quarter worth about $241,000. Finally, Armistice Capital LLC bought a new position in CNS Pharmaceuticals during the second quarter worth about $335,000. Institutional investors and hedge funds own 14.02% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.00.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.